MeitY Startup Hub onboards MergerDomo to strengthen start-up ecosystem in India
Posted By - Investment Banker
The Company has WHO GMP Approved and US FDA authorized manufacturing unit producing Injectables, Tablets, Eyes/Ear drops. The operations of the firm closed in 2017 due to Working Capital crunch, more than 60 equipments are in reusable condition. The Company has 20 acre land, All QA-QC Equipments are in place, RO Water / HEPA filter functional, and more than 60 product licenses are available. Upgradation for additional production is also possible The turnaround time would be 100 working days. along with the availability of all documents for due diligence.
 Deal Size
|
INR 45 - 55 Cr |
| Motives For Sellout | Raising Capital |
Industry Pharmaceuticals |
Sub-Industry Contract Research & Manufacturing Services (CRAMS) |
| Entity is open for Investor Keen on Special Situations/distress assets funding | |
Industry: Pharmaceuticals
Sub-Industry: Formulation
Division
Formulation type
Major Products
| 2018 (in Cr) | 2019 (in Cr) | 2020 (in Cr) | 2021 (in Cr) | ||
|---|---|---|---|---|---|
| Sales | N.D | N.D | N.D | N.D | |
| EBDITA | N.D | N.D | N.D | N.D | |
| PAT | N.D | N.D | N.D | N.D | |
| TOTAL DEBT | N.D | N.D | N.D | N.D | |
If you are interested in connecting with business please send an Expression of Interest and receive Information Memo to take this opportunity further
EXPRESS INTEREST MARK FAVOURITE
